Home › Stock analysis › PRME
Prime Medicine (PRME) Stock: Why It's Up Today
Updated Oct 19, 2026, 11:42 AM ET · intraday price
What changed since yesterday
- Trading at $3.80 as of 11:42 AM ET, +9.37% vs the prior close of $3.47.
- Volume 1.52M shares, 0.4x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
PRME jumps 9.4% to $3.80. Trading at $3.80 (intraday, 11:42 AM ET), +9.37% vs the prior close of $3.47. Day range $3.49–$3.82, opened at $3.56.
Price (intraday)$3.80+9.37%
Day range3.49–3.82
Open3.56
Volume1.52M
52-week range2.67–6.30
Avg volume (20d)5.02M
PRME daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 19, 2026 — PRME jumps 9.4% to $3.80
- Trading at $3.80 (intraday, 11:42 AM ET), +9.37% vs the prior close of $3.47. Day range $3.49–$3.82, opened at $3.56.
- Volume was 1.52M shares, 0.4x its 50-day average of 3.66M — lighter than usual.
- Price is +13.4% vs its 50-day average ($3.35) and +9.1% vs its 200-day average ($3.48).
- 52-week range $2.67–$6.30; the current price sits at 31% of that range, 39.8% below the 52-week high.
Oct 16, 2026 — PRME slides 3.9% to $3.47
- Closed at $3.47, -3.88% vs the prior close of $3.61. Day range $3.41–$3.61, opened at $3.55.
- Volume was 4.38M shares, 1.2x its 50-day average of 3.63M.
- Price is +4.1% vs its 50-day average ($3.33) and -0.2% vs its 200-day average ($3.48).
- 52-week range $2.67–$6.56; today's close sits at 21% of that range, 47.1% below the 52-week high.
Oct 15, 2026 — PRME jumps 15.3% to $3.61
- Closed at $3.61, +15.34% vs the prior close of $3.13. Day range $3.06–$3.65, opened at $3.12.
- Volume was 6.27M shares, 1.8x its 50-day average of 3.56M.
- Price is +8.7% vs its 50-day average ($3.32) and +3.8% vs its 200-day average ($3.48).
- 52-week range $2.67–$6.65; today's close sits at 24% of that range, 45.7% below the 52-week high.
Oct 14, 2026 — PRME slides 5.7% to $3.13, 3 down days in a row
- Closed at $3.13, -5.72% vs the prior close of $3.32. Day range $3.05–$3.22, opened at $3.21.
- Volume was 4.24M shares, 1.2x its 50-day average of 3.54M.
- Price is -5.5% vs its 50-day average ($3.31) and -9.9% vs its 200-day average ($3.48).
- 52-week range $2.67–$6.65; today's close sits at 12% of that range, 52.9% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — PRME slides 8.0% to $3.32
- Closed at $3.32, -8.03% vs the prior close of $3.61. Day range $3.27–$3.61, opened at $3.61.
- Volume was 4.06M shares, 1.1x its 50-day average of 3.54M.
- Price is +0.4% vs its 50-day average ($3.31) and -4.5% vs its 200-day average ($3.48).
- 52-week range $2.67–$6.65; today's close sits at 16% of that range, 50.1% below the 52-week high.
Oct 12, 2026 — PRME slides 9.5% to $3.61
- Closed at $3.61, -9.52% vs the prior close of $3.99. Day range $3.58–$3.96, opened at $3.95.
- Volume was 3.13M shares, 0.9x its 50-day average of 3.51M.
- Price is +9.5% vs its 50-day average ($3.30) and +3.8% vs its 200-day average ($3.48).
- 52-week range $2.67–$6.65; today's close sits at 24% of that range, 45.7% below the 52-week high.
Oct 9, 2026 — PRME jumps 11.5% to $3.99, a 3-month high on 2.4x normal volume
- Closed at $3.99, +11.45% vs the prior close of $3.58. Day range $3.54–$4.14, opened at $3.57.
- Volume was 8.06M shares, 2.4x its 50-day average of 3.40M — unusually heavy trading.
- Price is +21.5% vs its 50-day average ($3.28) and +14.7% vs its 200-day average ($3.48).
- 52-week range $2.67–$6.65; today's close sits at 33% of that range, 40.0% below the 52-week high.
Oct 8, 2026 — PRME slides 8.2% to $3.58 on 2.4x normal volume
- Closed at $3.58, -8.21% vs the prior close of $3.90. Day range $3.52–$3.90, opened at $3.83.
- Volume was 7.72M shares, 2.4x its 50-day average of 3.29M — unusually heavy trading.
- Price is +9.7% vs its 50-day average ($3.26) and +2.9% vs its 200-day average ($3.48).
- 52-week range $2.67–$6.85; today's close sits at 22% of that range, 47.7% below the 52-week high.
Oct 7, 2026 — PRME jumps 11.4% to $3.90, a 1-month high on 3.6x normal volume
- Closed at $3.90, +11.43% vs the prior close of $3.50. Day range $3.30–$4.02, opened at $3.36.
- Volume was 11.19M shares, 3.6x its 50-day average of 3.12M — unusually heavy trading.
- Price is +19.9% vs its 50-day average ($3.25) and +12.1% vs its 200-day average ($3.48).
- 52-week range $2.67–$6.85; today's close sits at 29% of that range, 43.1% below the 52-week high.
- That makes 3 straight gains.
Oct 6, 2026 — PRME jumps 9.0% to $3.50 on 4.1x normal volume
- Closed at $3.50, +9.03% vs the prior close of $3.21. Day range $3.26–$3.72, opened at $3.56.
- Volume was 12.01M shares, 4.1x its 50-day average of 2.94M — unusually heavy trading.
- Price is +8.1% vs its 50-day average ($3.24) and +0.7% vs its 200-day average ($3.48).
- 52-week range $2.67–$6.94; today's close sits at 19% of that range, 49.6% below the 52-week high.
Oct 5, 2026 — PRME jumps 7.7% to $3.21
- Closed at $3.21, +7.72% vs the prior close of $2.98. Day range $2.88–$3.26, opened at $3.00.
- Volume was 4.72M shares, 1.6x its 50-day average of 2.89M.
- Price is -0.5% vs its 50-day average ($3.23) and -7.7% vs its 200-day average ($3.48).
- 52-week range $2.67–$6.94; today's close sits at 13% of that range, 53.7% below the 52-week high.
Oct 2, 2026 — PRME dips 0.3% to $2.98, 3 down days in a row
- Closed at $2.98, -0.33% vs the prior close of $2.99. Day range $2.92–$3.08, opened at $3.05.
- Volume was 2.11M shares, 0.7x its 50-day average of 2.90M.
- Price is -7.5% vs its 50-day average ($3.22) and -14.4% vs its 200-day average ($3.48).
- 52-week range $2.67–$6.94; today's close sits at 7% of that range, 57.1% below the 52-week high.
- That makes 3 straight losses.
PRME bull case vs bear case (from the data)
Bull case
- Price is +13.4% vs its 50-day average — short-term trend is up.
- Price is +9.1% vs its 200-day average — above the long-term trend line.
- Annual revenue grew 55.3% in the latest fiscal year (SEC XBRL).
Bear case
- Latest fiscal-year net income: loss of $201.14M.
- Share count up 34.8% in a year (dilution).
- High volatility: average daily move of 7.1% over 20 sessions.
PRME latest news & SEC filings
Every SEC filing by or about PRME in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$42.11M (prior year -$52.59M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.24 (prior year -$0.41) (loss narrowed vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade PRME
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 3, 2026, Nov 7, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 7.08% (largest 15.3%). That is a volatile stock.
- Liquidity: about 5.02M shares (≈$19.04M) trade per day on average.
- 52-week position: $3.80 vs a range of $2.67–$6.30 (31% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 10-Q Aug 6, 2026; 8-K Aug 6, 2026; 8-K Jul 8, 2026.
- Share count: 181.38M shares outstanding (Jul 31, 2026), +34.8% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
PRME market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | 3.56 | 3.82 | 3.49 | 3.80 | 1.52M |
| Oct 16, 2026 | 3.55 | 3.61 | 3.41 | 3.47 | 4.39M |
| Oct 15, 2026 | 3.12 | 3.65 | 3.06 | 3.61 | 6.30M |
| Oct 14, 2026 | 3.21 | 3.22 | 3.05 | 3.13 | 4.24M |
| Oct 13, 2026 | 3.61 | 3.61 | 3.27 | 3.32 | 4.06M |
| Oct 12, 2026 | 3.95 | 3.96 | 3.58 | 3.61 | 3.13M |
| Oct 9, 2026 | 3.57 | 4.14 | 3.54 | 3.99 | 8.06M |
| Oct 8, 2026 | 3.83 | 3.90 | 3.52 | 3.58 | 7.72M |
| Oct 7, 2026 | 3.36 | 4.02 | 3.30 | 3.90 | 11.19M |
| Oct 6, 2026 | 3.56 | 3.72 | 3.26 | 3.50 | 12.01M |
| Oct 5, 2026 | 3.00 | 3.26 | 2.88 | 3.21 | 4.72M |
| Oct 2, 2026 | 3.05 | 3.08 | 2.92 | 2.98 | 2.11M |
| Oct 1, 2026 | 3.05 | 3.11 | 2.98 | 2.99 | 2.83M |
| Sep 30, 2026 | 3.11 | 3.19 | 3.02 | 3.06 | 3.13M |
| Sep 29, 2026 | 2.93 | 3.13 | 2.88 | 3.09 | 3.61M |
| Sep 28, 2026 | 2.85 | 2.92 | 2.77 | 2.88 | 3.68M |
| Sep 25, 2026 | 3.42 | 3.44 | 2.88 | 2.90 | 7.12M |
| Sep 24, 2026 | 3.11 | 3.13 | 2.99 | 3.07 | 4.49M |
| Sep 23, 2026 | 3.53 | 3.53 | 3.12 | 3.13 | 3.33M |
| Sep 22, 2026 | 3.22 | 3.57 | 3.20 | 3.54 | 2.72M |
About Prime Medicine
Prime Medicine (PRME) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in CAMBRIDGE, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1894562.
PRME board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Thomas Cahill | Director | Jun 8, 2026 |
| Wendy Chung | Director | Jun 8, 2026 |
| Kaye I Foster-Cheek | Director | Jun 8, 2026 |
| Michael Aaron Kelly | Director | Jun 8, 2026 |
| Jeffrey D Marrazzo | Director | Jun 8, 2026 |
| Robert Nelsen | Director | Jun 8, 2026 |
| Allan Reine | Chief Executive Officer | Feb 27, 2026 |
| David P Schenkein | Director | Jun 8, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Carman Alenson | See Remarks | Feb 24, 2026 |
| Ann L. Lee | Chief Technical Officer | Feb 24, 2026 |
| Svetlana Ni Makhni | Chief Financial Officer | Apr 17, 2026 |
| Allan Reine | Chief Executive Officer | Feb 27, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
PRME financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $4.63M | $-201.14M | -1.35 | $-162.56M |
| Dec 31, 2024 | $2.98M | $-195.88M | -1.65 | $-122.86M |
| Dec 31, 2023 | $0 | $-198.13M | -2.18 | $-165.41M |
| Dec 31, 2022 | $0 | $-121.82M | -4.19 | $-131.83M |
| Dec 31, 2021 | $0 | $-165.37M | -14.19 | $-34.08M |
Latest balance sheet: total assets $249.04M, total liabilities $209.23M, cash $47.45M (as of Jun 30, 2026).
PRME earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $2.95 |
| May 7, 2026 | 8-K Item 2.02 (results) | $3.12 |
| Mar 3, 2026 | 8-K Item 2.02 (results) | $4.23 |
| Nov 7, 2025 | 8-K Item 2.02 (results) | $3.81 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $3.68 |
| Jul 30, 2025 | 8-K Item 2.02 (results) | $3.92 |
| May 8, 2025 | 8-K Item 2.02 (results) | $1.32 |
| Feb 28, 2025 | 8-K Item 2.02 (results) | $2.52 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $4.32 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 10, 2024 | 8-K Item 2.02 (results) | — |
| Mar 1, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on PRME
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: intraday data as of Oct 19, 2026, 11:42 AM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.